-
French biotech company Ciloa wins the 2020 “Sanofi iTech Awards”.
-
The winning project is based on the unique innovation developed by Ciloa, which uses its customized exosomes for therapeutic purposes.
-
The “Sanofi iTech Awards” program funds and supports projects related to the development of innovative technologies in Healthcare that may lead to a subsequent research collaboration between Sanofi and Ciloa.
Exosome Research: Who Is Dominating in the Scientific Literature?
Exosome research is on the rise, fueled by an increasing recognition of the central role that exosomes play in intercellular (cell-to-cell) communication and transportation. As intracellular messengers, exosomes have the potential to mediate many of the therapeutics effects commonly associated with cells, with far fewer risks.
In this article:
- Exosome Research by Dr. Gabrielsson
- Unicyte AG on Exosomes Therapy
- Leading Exosome Research Journals
For competitors within the exosome marketplace, it is vital to assess existing and future trends. One of the best tools for assessing scientific progress is to review rates of exosome research.
When exosome publications are analyzed, U.S. authors have published approximately 40% of the articles and Chinese authors take second place.
When the term “exosome” is searched within scientific literature, Dr. Susanne Gabrielsson from the Karolinska Institutet in Sweden is the leading author, with 37 articles, making her one of the global authorities on exosome research. A full list of Dr. Gabrielsson’s exosome publications can be viewed at this link.
When the term “extracellular vesicles” is searched, Unicyte AG, a regenerative medicine unit of Fresenius Medical Care, takes the lead. Headquartered in Switzerland, the company has published more than 100 papers on exosomes and extracellular vesicles in combination with Prof. Giovanni Camussi. The company is also a market leader in terms of patents and translational programs.
Leading Exosome Journals
Interestingly, two scientific journals have been particularly favorable toward exosome publications, publishing the greatest quantity to date:
PLoS ONE
PloS ONE, a peer-reviewed open access scientific journal published by the Public Library of Science, has published 349 articles with the term “exosome” or “exosomes” in the title. A full list of the articles can be viewed here.
Journal of Biological Chemistry
The Journal of Biological Chemistry, a weekly peer-reviewed scientific journal published by the American Society for Biochemistry and Molecular Biology, has published 167 articles with the term “exosome” or “exosomes” in the title. A full list of the articles can be viewed here.
Google Trend data also shows a clear linear increase in interest in exosome-related topics. To compete for dominance within this market, it is essential to identify trends as they begin to impact the marketplace, not after they are in full effect.
If you found this blog valuable, subscribe to BioInformant’s stem cell industry updates.
To learn more, view the “Global Exosome Market – Market Size, Forecast, Trials and Trends, 2021.”
New Lab at UF’s Sid Martin Biotech to Pave Way for Post-COVID Therapy, Regenerative Medicine Research
Noninvasive cellular and acellular therapies will lead to life-extending medicines and treatments, including post-COVID anti-inflammation therapy. A new partnership between the world’s top university for biotech business incubation and Neobiosis, a global expert in regenerative medicine, may fuel a healthcare revolution.
Alachua, FLA., January 19, 2021 – The inflammation COVID-19 patients suffer during and post-COVID-19 infection (AKA “Post-COVID Syndrome”) will be one of many focuses of a new Research & Development laboratory recently launched at the University of Florida Sid Martin Innovate Biotechnology Institute, the world-recognized leader in biotechnology incubation(1). Neobiosis, which produces regenerative tissues, cells and extracellular vesicles for research and clinical trials to help the body heal itself—without surgery—will operate the laboratory at the biotech center, located in Alachua, Fla. [Read more…]
Organicell Announces FDA Approval Of IND Application for the Use of Zofin™ In The Treatment Of Chronic Obstructive Pulmonary Disease (COPD)
Miami, FL (January 28th, 2021) — Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its lead product, Zofin™, in the treatment of patients diagnosed with chronic obstructive pulmonary disease (COPD). [Read more…]
JOP POST: Chief Manufacturing & Development Officer at Exopharm
Job Title: Chief Manufacturing & Development Officer
Company: Exopharm
- Exosome therapeutic bioproducts
- World leader and innovator
- Listed company based in Melbourne Australia
- Lead the 20 person innovation and development team in this expanding biotech
Established in 2013 and listed in 2018, Exopharm (ASX:EX1) was founded on the conviction that exosomes/EVs will become a new class of medicines to treat a many medical conditions. [Read more…]
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- …
- 23
- Next Page »